This site is intended for healthcare professionals
  • Home
  • /
  • Drugs
  • /
  • V VARIOUS
  • /
  • V03
  • /
  • V03A
  • /
  • V03AF
  • /
  • V03AF02
  • /
  • CARDIOXANE 500 mg powder for solution for infusion
Drug information

Cardioxane

POM
Read time: 20 mins
Last updated: 23 May 2020
Published: 24 Jul 2020
...
 

4.1 Therapeutic indications

Cardioxane is indicated in adults for the prevention of chronic cumulative cardiotoxicity caused by anthracycline use in advanced and/or metastatic breast cancer patients who have received a prior cumulative dose of 300 mg/m2 of doxorubicin or a prior cumulative dose of 540 mg/m2 of epirubicin when further anthracycline treatment is required.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Click here to register now

Drug section

Clinical trial
PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

2 mins
Clinical trial
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

To determine the clinical activity of SUTENT® (sunitinib malate) in non-clear cell renal cell cancer (RCC). Clinical activity will take...

1 min
Clinical trial
A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers

This open-label, multi-center study will assess the efficacy and safety of Zelboraf (vemurafenib) in patients with BRAF V600 mutation-positive cancers...

3 min

Journal
Cutaneous metastasis from vulvar squamous cell carcinoma: a rare occurrence that should not be forgotten.

Vulvar cancer accounts for 5% of the female genital tract cancers. Cutaneous metastases from vulvar cancer are extremely rare and for this reason, it can be difficult to reach a diagnosis with a consequent delay in the treatment.

1 mins
Journal
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.

Background: Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success.

1 min
Journal
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.

Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma

1 min

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).